GlassScriptPhysician profile
Terrence W Triplett
NPI 1518902246
$15,111.49
in general payments reported to CMS, 2019-2025
63 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,104 · 2020: $1,574 · 2021: $2,138 · 2022: $2,236 · 2023: $1,870 · 2024: $2,531 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,058.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,964.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,350.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $1,211.70 | 2019-2025 | |
| Novo Nordisk INC | $1,141.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,041.07 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $971.05 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $672.71 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $652.98 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $630.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $582.23 | 2019-2022 | |
| Esperion Therapeutics, INC. | $408.16 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.93 | 2019-2021 | |
| Amarin Pharma, INC. | $322.15 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.63 | 2019-2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $260.12 | 2022-2025 | Nuzyra, Xhance |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Triplett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.